Using CT scans and biomarkers to improve treatment for pulmonary fibrosis
The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis
This study is testing if special CT scans and biomarkers can help doctors better understand how severe idiopathic pulmonary fibrosis is and how well treatments are working for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 40 Years to 101 Years |
| Sex | All |
| Sponsor | University of Virginia Academic / other |
| Locations | 1 site (Charlottesville, Virginia) |
| Trial ID | NCT06323876 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the role of quantitative CT scans and radiomic biomarkers in assessing disease severity and treatment response in patients with idiopathic pulmonary fibrosis (IPF). Participants will undergo two chest CT scans: a historical baseline scan and a follow-up scan approximately 12 months later. The study seeks to identify and validate radiologic features that can provide insights into disease activity and help guide clinical decision-making. By leveraging advanced imaging techniques, the researchers hope to enhance the understanding of IPF and improve therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 40 and older who have been diagnosed with idiopathic pulmonary fibrosis.
Not a fit: Patients who are pregnant or have significant medical or psychiatric conditions that could affect their safety or ability to complete the study may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more precise monitoring and treatment strategies for patients with pulmonary fibrosis.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques and biomarkers for similar conditions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥ 40 years of age 2. Diagnosed with IPF according to 2018 ATS/ERS/JRS/ALAT confirmed by the enrolling investigator 3. Signed informed consent Exclusion Criteria: 1. Pregnancy or planning to become pregnant 2. Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \<1% per year during study participation\* 3. Significant medical, surgical or psychiatric illness that in the opinion of the investigator would affect subject safety or potential to complete the research study * A woman is considered to be of childbearing potential if she is post-monarchical, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
Where this trial is running
Charlottesville, Virginia
- University of Virginia — Charlottesville, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: Noth Imre, MD — Division of Pulmonary and Critical Care
- Study coordinator: Roselove Nunoo-Asare
- Email: rnn3b@uvahealth.org
- Phone: 4342436074
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.